Papaver somniverum‡
CA: CDSA Schedule I Section 1 Opium poppy
US: CSA Schedule II Section b Subsection 3 Opium poppy
Papaverine
CA: [not controlled] CDSA Schedule I Section 1 Subsection 36 Papaverine
Para-Ethoxyamphetamine‡
CA: CDSA Schedule I Section 19 Subsection 16 4-Ethoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 17 4-Ethoxyamphetamine
UK: MDA Part I Class A Section 1(c) 4-Ethoxyamphetamine
Para-Fluorofentanyl
CA: CDSA Schedule I Section 16 Subsection 4 p-Fluorofentanyl
UK: MDA Part I Class A Section 1(d) p-Fluorofentanyl
UN: Narcotics Part 1 Section 1 Para-Fluorofentanyl and Section 3 Para-Fluorofentanyl
US: CSA Schedule I Section b Subsection 42 Para-fluorofentanyl
Para-fluorofentanyl
CA: CDSA Schedule I Section 16 Subsection 4 p-Fluorofentanyl
UK: MDA Part I Class A Section 1(d) p-Fluorofentanyl
UN: Narcotics Part 1 Section 1 Para-Fluorofentanyl and Section 3 Para-Fluorofentanyl
US: CSA Schedule I Section b Subsection 42 Para-fluorofentanyl
Parafluorofentanyl‡
CA: CDSA Schedule I Section 16 Subsection 4 p-Fluorofentanyl
UK: MDA Part I Class A Section 1(d) p-Fluorofentanyl
UN: Narcotics Part 1 Section 1 Para-Fluorofentanyl and Section 3 Para-Fluorofentanyl
US: CSA Schedule I Section b Subsection 42 Para-fluorofentanyl
Paraldehyde
US: CSA Schedule IV Section c Subsection 43 Paraldehyde
⇒
PubChem: 31264; ChemSpider: 21106173; Bluelight: Paraldehyde ; Erowid: Paraldehyde Synthesis; Wikipedia: Paraldehyde
Paramethoxyamphetamine
CA: CDSA Schedule I Section 19 Subsection 6 4-Methoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 7 4-Methoxyamphetamine
UK: MDA Part I Class A Section 1(c) 4-Methoxyamphetamine
UN: Psychotropics Schedule I PMA
US: CSA Schedule I Section d Subsection 7 4-Methoxyamphetamine
PB-22
CA: CDSA Schedule II Section 2 Subsection 7 1-Pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid
US: CSA Schedule I Section h Subsection 7 Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate
PCC
US: CSA Schedule II Section g Subsection 2 Item ii 1-Piperidinocyclohexanecarbonitrile
PCE
CA: CDSA Schedule III Section 13 N-(1-Phenylcyclohexyl)ethylamine
UK: MDA Part I Class A Section 1(a) Eticyclidine
UN: Psychotropics Schedule I Eticyclidine (PCE)
US: CSA Schedule I Section d Subsection 32 Ethylamine analog of Phencyclidine
PCP
CA: CDSA Schedule I Section 14 Phencyclidine
UK: MDA Part I Class A Section 1(a) Phencyclidine
UN: Psychotropics Schedule II Phencyclidine (PCP)
US: CSA Schedule II Section e Subsection 4 Phencyclidine
⇒
PubChem: 6468; ChemSpider: 6224; Bluelight: PCP; Drugs Forum: Phencyclidine; Erowid: PCP; Wikipedia: Phencyclidine
PCPY
CA: CDSA Schedule III Section 16 Rolicyclidine
UK: MDA Part I Class A Section 1(a) Rolicyclidine
UN: Psychotropics Schedule I Rolicyclidine (PHP) (PCPY)
US: CSA Schedule I Section d Subsection 33 Pyrrolidine analog of Phencyclidine
⇒
PubChem: 62436; ChemSpider: 56218; Bluelight: PCP analogs; Drugs Forum: PCP analogs; Erowid: Rolicyclidine synthesis; Wikipedia: Rolicyclidine
Pentazocine
CA: CDSA Schedule I Section 11 Subsection 3 Pentazocine
US: CSA Schedule IV Section g Subsection 1 Pentazocine
⇒
PubChem: 4736; ChemSpider: 390041; Bluelight: Pentazocine; Drugs Forum: Pentazocine; Wikipedia: Pentazocine
Pentedrone
US: CSA Schedule I Section h Subsection 15 Pentedrone
⇒
PubChem: 57501499; ChemSpider: 26286729; Bluelight: Pentedrone; Drugs Forum: Pentedrone; Wikipedia: Pentedrone
1-(4-Pentenyl)-3-(1-naphthoyl)indole
CA: CDSA Schedule II Section 2 Subsection 2 1-(4-Pentenyl)-3-(1-naphthoyl)indole
Pentobarbital
CA: CDSA Schedule IV Section 1 Subsection 20 Pentobarbital
UN: Psychotropics Schedule III Pentobarbital
US: CSA Schedule II Section e Subsection 3 Pentobarbital, Schedule III Section c Subsection 1 Item iii Pentobarbital and Subsection 2 Item iii Pentobarbital
⇒
PubChem: 4737; ChemSpider: 4575; Bluelight: Pentobarbital; Drugs Forum: Pentobarbital; Erowid: Barbiturates; Wikipedia: Pentobarbital
1-Pentyl-3-(2-chlorophenylacetyl)indole
US: CSA Schedule I Section g Subsection 15 1-Pentyl-3-(2-chlorophenylacetyl)indole
1-Pentyl-3-(4-ethyl-1-naphthoyl)indole
CA: CDSA Schedule II Section 2 Subsection 2 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole
1-Pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole
CA: CDSA Schedule II Section 2 Subsection 3 1-Pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
CA: CDSA Schedule II Section 2 Subsection 6 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)-methanone
UK: MDA Part II Class B Section 1(c) UR-144
US: CSA Schedule I Section h Subsection 1 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
US: [proposed] CSA Schedule I Section g Subsection 16 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)-methanone
CA: CDSA Schedule II Section 2 Subsection 6 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)-methanone
UK: MDA Part II Class B Section 1(c) UR-144
US: CSA Schedule I Section h Subsection 1 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
US: [proposed] CSA Schedule I Section g Subsection 16 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
![3D rendering of 1-Pentyl-3-[(4-methoxy)-benzoyl]indole](data:image/png;base64,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 "Click for a 3D rendering of 1-Pentyl-3-[(4-methoxy)-benzoyl]indole")
![3D rendering of 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole](data:image/png;base64,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 "Click for a 3D rendering of 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole")
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole
CA: CDSA Schedule II Section 2 Subsection 2 1-Butyl-3-(4-methoxy-1-naphthoyl)indole
UK: MDA Part II Class B Section 1(c) JWH-081
US: CSA Schedule I Section g Subsection 8 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole
1-Pentyl-3-(2-methoxy-1-naphthoyl)indole
CA: CDSA Schedule II Section 2 Subsection 2 1-Pentyl-3-(2-methoxy-1-naphthoyl)indole
1-Pentyl-3-(2-methoxyphenylacetyl)indole
CA: CDSA Schedule II Section 2 Subsection 4 1-Pentyl-3-(2-methoxyphenylacetyl)indole
UK: MDA Part II Class B Section 1(c) JWH-250
US: CSA Schedule I Section g Subsection 7 1-Pentyl-3-(2-methoxyphenylacetyl)indole
1-Pentyl-3-(3-methoxyphenylacetyl)indole
CA: CDSA Schedule II Section 2 Subsection 4 1-Pentyl-3-(3-methoxyphenylacetyl)indole
1-Pentyl-3-(4-methyl-1-naphthoyl)indole
CA: CDSA Schedule II Section 2 Subsection 2 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
UK: MDA Part II Class B Section 1(c) JWH-122
US: CSA Schedule I Section g Subsection 9 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
1-Pentyl-3-(2-methylphenylacetyl)indole
CA: CDSA Schedule II Section 2 Subsection 4 1-Pentyl-3-(2-methylphenylacetyl)indole
1-Pentyl-3-(1-naphthoyl)indole
CA: CDSA Schedule II Section 2 Subsection 2 1-Pentyl-3-(1-naphthoyl)indole
UK: MDA Part II Class B Section 1(c) JWH-018
US: CSA Schedule I Section g Subsection 3 1-Pentyl-3-(1-naphthoyl)indole
1-Pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid
CA: CDSA Schedule II Section 2 Subsection 7 1-Pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid
US: CSA Schedule I Section h Subsection 7 Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate
Perampanel
US: CSA Schedule III Section c Subsection 11 Perampanel
Pethidine [derivatives]
CA: CDSA Schedule I Section 3 Phenylpiperidines
UK: MDA Part I Class A Section 1(e) Pethidine [derivatives]
Pethidine intermediate A
CA: CDSA Schedule I Section 3 Subsection 14 Methylphenylisonipecotonitrile
UK: MDA Part I Class A Section 1(a) 4-Cyano-1-methyl-4-phenylpiperidine
UN: Narcotics Part 1 Section 1 Pethidine intermediate A
US: CSA Schedule II Section c Subsection 19 Pethidine-intermediate-A
Pethidine intermediate B
CA: CDSA Schedule I Section 3 Subsection 16 Norpethidine
UK: MDA Part I Class A Section 1(a) 4-Phenylpiperidine-4-carboxylic acid ethyl ester
UN: Narcotics Part 1 Section 1 Pethidine intermediate B
US: CSA Schedule II Section c Subsection 20 Pethidine-intermediate-B
Pethidine intermediate C
CA: CDSA Schedule I Section 3 Subsection 22 Pethidine intermediate C
UK: MDA Part I Class A Section 1(a) 1-Methyl-4-phenylpiperidine-4-carboxylic acid
UN: Narcotics Part 1 Section 1 Pethidine intermediate C
US: CSA Schedule II Section c Subsection 21 Pethidine-intermediate-C
Pethidine-intermediate-A
CA: CDSA Schedule I Section 3 Subsection 14 Methylphenylisonipecotonitrile
UK: MDA Part I Class A Section 1(a) 4-Cyano-1-methyl-4-phenylpiperidine
UN: Narcotics Part 1 Section 1 Pethidine intermediate A
US: CSA Schedule II Section c Subsection 19 Pethidine-intermediate-A
Pethidine-intermediate-B
CA: CDSA Schedule I Section 3 Subsection 16 Norpethidine
UK: MDA Part I Class A Section 1(a) 4-Phenylpiperidine-4-carboxylic acid ethyl ester
UN: Narcotics Part 1 Section 1 Pethidine intermediate B
US: CSA Schedule II Section c Subsection 20 Pethidine-intermediate-B
Pethidine-intermediate-C
CA: CDSA Schedule I Section 3 Subsection 22 Pethidine intermediate C
UK: MDA Part I Class A Section 1(a) 1-Methyl-4-phenylpiperidine-4-carboxylic acid
UN: Narcotics Part 1 Section 1 Pethidine intermediate C
US: CSA Schedule II Section c Subsection 21 Pethidine-intermediate-C
Pethidinic acid‡
CA: CDSA Schedule I Section 3 Subsection 22 Pethidine intermediate C
UK: MDA Part I Class A Section 1(a) 1-Methyl-4-phenylpiperidine-4-carboxylic acid
UN: Narcotics Part 1 Section 1 Pethidine intermediate C
US: CSA Schedule II Section c Subsection 21 Pethidine-intermediate-C
Petrichloral
US: CSA Schedule IV Section c Subsection 44 Petrichloral
Peyote
CA: [not controlled] CDSA Schedule III Section 17 Lophophora
US: CSA Schedule I Section d Subsection 26 Peyote
⇒
PubChem: 135309929 135330128; Bluelight: Peyote; Drugs Forum: Peyote; Erowid: Peyote; Wikipedia: Peyote
Phenadoxone
CA: CDSA Schedule I Section 5 Subsection 7 Phenadoxone
UK: MDA Part I Class A Section 1(a) Phenadoxone
UN: Narcotics Part 1 Section 1 Phenadoxone
US: CSA Schedule I Section b Subsection 44 Phenadoxone
Phenalkoxams
CA: CDSA Schedule I Section 7 Phenalkoxams
Phenampromide
CA: CDSA Schedule I Section 12 Subsection 2 Phenampromide
UK: MDA Part I Class A Section 1(a) Phenampromide
UN: Narcotics Part 1 Section 1 Phenampromide
US: CSA Schedule I Section b Subsection 45 Phenampromide
Phenazepines
CA: CDSA Schedule I Section 4 Phenazepines
Phenazocine
CA: CDSA Schedule I Section 11 Subsection 1 Phenazocine
UK: MDA Part I Class A Section 1(a) Phenazocine
UN: Narcotics Part 1 Section 1 Phenazocine
US: CSA Schedule II Section c Subsection 22 Phenazocine
Phencyclidine
CA: CDSA Schedule I Section 14 Phencyclidine
UK: MDA Part I Class A Section 1(a) Phencyclidine
UN: Psychotropics Schedule II Phencyclidine (PCP)
US: CSA Schedule II Section e Subsection 4 Phencyclidine
⇒
PubChem: 6468; ChemSpider: 6224; Bluelight: PCP; Drugs Forum: Phencyclidine; Erowid: PCP; Wikipedia: Phencyclidine
Phendimetrazine
CA: CDSA Schedule IV Section 5 Phendimetrazine
UK: MDA Part III Class C Section 1(a) Phendimetrazine
UN: Psychotropics Schedule IV Phendimetrazine
US: CSA Schedule III Section b Subsection 5 Phendimetrazine
Phenethylamine
UK: [not controlled] MDA Part I Class A Section 1(ba) Phenethylamine and Section 1(c) Phenethylamine
N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide
US: CSA Schedule I Section h Subsection 24 N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide
Phenmetrazine
CA: CDSA Schedule IV Section 6 Phenmetrazine
UK: MDA Part II Class B Section 1(a) Phenmetrazine
UN: Psychotropics Schedule II Phenmetrazine
US: CSA Schedule II Section d Subsection 3 Phenmetrazine
Phenobarbital
CA: CDSA Schedule IV Section 1 Subsection 21 Phenobarbital
UN: Psychotropics Schedule IV Phenobarbital
US: CSA Schedule IV Section c Subsection 45 Phenobarbital
⇒
PubChem: 4763; ChemSpider: 4599; Bluelight: Phenobarbital vs. benzo's; Drugs Forum: Phenobarbital; Erowid: Barbiturates; Wikipedia: Phenobarbital
Phenomorphan
CA: CDSA Schedule I Section 10 Subsection 7 Phenomorphan
UK: MDA Part I Class A Section 1(a) Phenomorphan
UN: Narcotics Part 1 Section 1 Phenomorphan
US: CSA Schedule I Section b Subsection 46 Phenomorphan
Phenoperidine
CA: CDSA Schedule I Section 3 Subsection 18 Phenoperidine
UK: MDA Part I Class A Section 1(a) Phenoperidine
UN: Narcotics Part 1 Section 1 Phenoperidine
US: CSA Schedule I Section b Subsection 47 Phenoperidine
Phentermine
CA: CDSA Schedule IV Section 8 Phentermine
UK: MDA Part III Class C Section 1(a) Phentermine
UN: Psychotropics Schedule IV Phentermine
US: CSA Schedule IV Section f Subsection 9 Phentermine
Phenylacetic acid
CA: CDSA Schedule VI Part 1 Subsection 12 Phenylacetic acid
EU: Drug precursors Annex I Category 2 Phenylacetic acid and Annex II Phenylacetic acid
UK: MDA Drug precursors Annex I Category 2 Phenylacetic acid and Drug precursors Annex II Phenylacetic acid
UN: Precursors Table II Phenylacetic acid
US: CSA Listed Chemicals Section a Subsection 8 Phenylacetic acid
⇒
PubChem: 999; ChemSpider: 10181341; Erowid: Phenylacetic acid synthesis; Wikipedia: Phenylacetic acid
Phenylacetone
CA: CDSA Schedule VI Part 1 Subsection 11 1-Phenyl-2-propanone
EU: Drug precursors Annex I Category 1 1-Phenyl-2-propanone
UK: MDA Drug precursors Annex I Category 1 1-Phenyl-2-propanone
UN: Precursors Table I 1-Phenyl-2-propanone
US: CSA Schedule II Section g Subsection 1 Item i Phenylacetone
3-Phenylacetylindole
CA: CDSA Schedule II Section 2 Subsection 4 3-Phenylacetylindole
UK: MDA Part II Class B Section 1(c) 3-Phenylacetylindole
US: CSA Schedule I Section v Item v 3-Phenylacetylindole
1-Phenylcyclohexylamine
US: CSA Schedule II Section g Subsection 2 Item i 1-Phenylcyclohexylamine
1-Phenylcyclohexylamine
UK: MDA Part II Class B Section 1(d) 1-Phenylcyclohexylamine
N-(1-Phenylcyclohexyl)ethylamine
CA: CDSA Schedule III Section 13 N-(1-Phenylcyclohexyl)ethylamine
UK: MDA Part I Class A Section 1(a) Eticyclidine
UN: Psychotropics Schedule I Eticyclidine (PCE)
US: CSA Schedule I Section d Subsection 32 Ethylamine analog of Phencyclidine
N-Phenylethyl-4-piperidone
US: CSA Listed Chemicals Section a Subsection 28 N-Phenylethyl-4-piperidone
Phenylmethylbarbituric acid
CA: CDSA Schedule IV Section 1 Subsection 23 Phenylmethylbarbituric acid
![3D rendering of 1-[1-(Phenylmethyl)cyclohexyl]piperidine](data:image/png;base64,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 "Click for a 3D rendering of 1-[1-(Phenylmethyl)cyclohexyl]piperidine")
1-[1-(Phenylmethyl)cyclohexyl]piperidine
CA: CDSA Schedule III Section 22 1-[1-(Phenylmethyl)cyclohexyl]piperidine
1-Phenylpiperazine
UK: MDA Part III Class C Section 1(ca) 1-Phenylpiperazine
4-Phenylpiperidine-4-carboxylic acid ethyl ester
CA: CDSA Schedule I Section 3 Subsection 16 Norpethidine
UK: MDA Part I Class A Section 1(a) 4-Phenylpiperidine-4-carboxylic acid ethyl ester
UN: Narcotics Part 1 Section 1 Pethidine intermediate B
US: CSA Schedule II Section c Subsection 20 Pethidine-intermediate-B
Phenylpiperidines
CA: CDSA Schedule I Section 3 Phenylpiperidines
UK: MDA Part I Class A Section 1(e) Pethidine [derivatives]
Phenylpropanolamine
CA: CDSA Schedule VI Part 1 Subsection 10 Norephedrine
EU: Drug precursors Annex I Category 1 Norephedrine
UK: MDA Drug precursors Annex I Category 1 Norephedrine
UN: Precursors Table I Norephedrine
US: CSA Listed Chemicals Section a Subsection 9 Phenylpropanolamine
⇒
PubChem: 10297 26934; ChemSpider: 9875; Bluelight: Phenylpropanolamine; Erowid: Phenylpropanolamine; Wikipedia: Phenylpropanolamine
Phenylpropanolamine
UK: [not controlled] MDA Part III Class C Section 2 Phenylpropanolamine
1-Phenyl-2-propanone
CA: CDSA Schedule VI Part 1 Subsection 11 1-Phenyl-2-propanone
EU: Drug precursors Annex I Category 1 1-Phenyl-2-propanone
UK: MDA Drug precursors Annex I Category 1 1-Phenyl-2-propanone
UN: Precursors Table I 1-Phenyl-2-propanone
US: CSA Schedule II Section g Subsection 1 Item i Phenylacetone
1-Phenyl-N-propylcyclohexanamine
CA: CDSA Schedule III Section 15 1-Phenyl-N-propylcyclohexanamine
UK: MDA Part II Class B Section 1(d) 1-Phenyl-N-propylcyclohexanamine
Pholcodine
CA: CDSA Schedule I Section 1 Subsection 30 Pholcodine
UK: MDA Part II Class B Section 1(a) Pholcodine
UN: Narcotics Part 1 Section 2 Pholcodine and Part 2 Section 1 Pholcodine
US: CSA Schedule I Section c Subsection 22 Pholcodine
⇒
PubChem: 5311356; ChemSpider: 4470854; Bluelight: Pholcodine; Drugs Forum: Pholcodine; Wikipedia: Pholcodine
PHP
CA: CDSA Schedule III Section 16 Rolicyclidine
UK: MDA Part I Class A Section 1(a) Rolicyclidine
UN: Psychotropics Schedule I Rolicyclidine (PHP) (PCPY)
US: CSA Schedule I Section d Subsection 33 Pyrrolidine analog of Phencyclidine
⇒
PubChem: 62436; ChemSpider: 56218; Bluelight: PCP analogs; Drugs Forum: PCP analogs; Erowid: Rolicyclidine synthesis; Wikipedia: Rolicyclidine
Piminodine
CA: CDSA Schedule I Section 3 Subsection 19 Piminodine
UK: MDA Part I Class A Section 1(a) Piminodine
UN: Narcotics Part 1 Section 1 Piminodine
US: CSA Schedule II Section c Subsection 23 Piminodine
Piperidine
CA: CDSA Schedule VI Part 1 Subsection 13 Piperidine
EU: Drug precursors Annex I Category 2 Piperidine and Annex II Piperidine
UK: MDA Drug precursors Annex I Category 2 Piperidine and Drug precursors Annex II Piperidine
UN: Precursors Table II Piperidine
US: CSA Listed Chemicals Section a Subsection 10 Piperidine
⇒
PubChem: 8082; ChemSpider: 7791; Drugs Forum: Piperidines; Erowid: Piperidine; Wikipedia: Piperidine
1-Piperidinocyclohexanecarbonitrile
US: CSA Schedule II Section g Subsection 2 Item ii 1-Piperidinocyclohexanecarbonitrile
Piritramide
CA: CDSA Schedule I Section 15 Piritramide
UK: MDA Part I Class A Section 1(a) Piritramide
UN: Narcotics Part 1 Section 1 Piritramide
US: CSA Schedule I Section b Subsection 48 Piritramide
PMA
CA: CDSA Schedule I Section 19 Subsection 6 4-Methoxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 7 4-Methoxyamphetamine
UK: MDA Part I Class A Section 1(c) 4-Methoxyamphetamine
UN: Psychotropics Schedule I PMA
US: CSA Schedule I Section d Subsection 7 4-Methoxyamphetamine
Poppy‡
CA: CDSA Schedule I Section 1 Opium poppy
US: CSA Schedule II Section b Subsection 3 Opium poppy
Poppy, opium
CA: CDSA Schedule I Section 1 Subsection 1 Opium
UK: MDA Part I Class A Section 1(a) Opium
US: CSA Schedule II Section b Subsection 1 Item xvi Raw opium, Schedule III Section e Subsection 1 Item i Opium, Item v Opium and Schedule V Section c Subsection 5 Opium
US: [revoked] CSA Schedule III Section e Subsection 1 Opium
⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: OpiumPoppy seed
CA: [not controlled] CDSA Schedule I Section 1 Subsection 37 Poppy seed
Poppy straw
UK: MDA Part I Class A Section 1(a) Poppy-straw
US: CSA Schedule II Section b Subsection 3 Poppy straw
Poppy-straw
UK: MDA Part I Class A Section 1(a) Poppy-straw
US: CSA Schedule II Section b Subsection 3 Poppy straw
Potassium permanganate
CA: CDSA Schedule VI Part 1 Subsection 15 Potassium permanganate
EU: Drug precursors Annex I Category 2 Potassium permanganate and Annex II Potassium permanganate
UK: MDA Drug precursors Annex I Category 2 Potassium permanganate and Drug precursors Annex II Potassium permanganate
UN: Precursors Table I Potassium permanganate
US: CSA Listed Chemicals Section b Subsection 5 Potassium permanganate
⇒
PubChem: 516875; ChemSpider: 22810; Bluelight: KMnO4 substitute; Wikipedia: Potassium permanganatePowdered opium
US: CSA Schedule II Section b Subsection 1 Item xv Powdered opium
Prasterone
CA: CDSA Schedule IV Section 23 Subsection 36 Prasterone
UK: MDA Part III Class C Section 1(b) Prasterone
Pregabalin
US: CSA Schedule V Section e Subsection 3 Pregabalin
⇒
PubChem: 5486971; ChemSpider: 3902475; Bluelight: Pregabalin; Drugs Forum: Pregabalin; Erowid: Pregabalin; Wikipedia: Pregabalin
Probarbital
CA: CDSA Schedule IV Section 1 Subsection 22 Probarbital
Prodine‡
CA: CDSA Schedule I Section 3 Subsection 3 Alphaprodine
UK: MDA Part I Class A Section 1(a) Alphaprodine
UN: Narcotics Part 1 Section 1 Alphaprodine
US: CSA Schedule II Section c Subsection 2 Alphaprodine
Proheptazine
CA: CDSA Schedule I Section 4 Subsection 1 Proheptazine
UK: MDA Part I Class A Section 1(a) Proheptazine
UN: Narcotics Part 1 Section 1 Proheptazine
US: CSA Schedule I Section b Subsection 49 Proheptazine
Propallylonal
CA: CDSA Schedule IV Section 1 Subsection 19 Propallylonal
Propanoic anhydride‡
US: CSA Listed Chemicals Section a Subsection 15 Propionic anhydride
Properidine
CA: CDSA Schedule I Section 3 Subsection 20 Properidine
UK: MDA Part I Class A Section 1(a) Properidine
UN: Narcotics Part 1 Section 1 Properidine
US: CSA Schedule I Section b Subsection 50 Properidine
Propetandrol
UK: MDA Part III Class C Section 1(b) Propetandrol
Propionic anhydride
US: CSA Listed Chemicals Section a Subsection 15 Propionic anhydride
Propylhexedrine
CA: CDSA Schedule V Section 2 Propylhexedrine
N-Propyl-3,4-methylenedioxyamphetamine
CA: CDSA Schedule I Section 19 Subsection 18 N-Propyl-3,4-methylenedioxyamphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 19 N-Propyl-3,4-methylenedioxyamphetamine
UK: MDA Part I Class A Section 1(c) N-Propyl-3,4-methylenedioxyamphetamine
Propylphenidate
UK: MDA Temporary Class Drug Orders 2015 Propylphenidate
Prostanozol
UK: MDA Part III Class C Section 1(b) Prostanozol
US: CSA Schedule III Section f Subsection 1 Item 58 Prostanozol and Item 89 [3,2-c]Pyrazole-5α-androstan-17β-ol
Prostanozol, O-tetrahydropyran-2-yl
UK: MDA Part III Class C Section 1(b) Prostanozol, O-tetrahydropyran-2-yl
US: [not controlled] CSA Schedule III Section f Subsection 1 Prostanozol, O-tetrahydropyran-2-yl
Pseudoephedrine
CA: CDSA Schedule VI Part 1 Subsection 16 Pseudoephedrine
EU: Drug precursors Annex I Category 1 Pseudoephedrine
UK: MDA Drug precursors Annex I Category 1 Pseudoephedrine
UN: Precursors Table I Pseudoephedrine
US: CSA Listed Chemicals Section a Subsection 11 Pseudoephedrine
⇒
PubChem: 7028; ChemSpider: 6761; Bluelight: Pseudoephedrine; Drugs Forum: Pseudoephedrine; Erowid: Ephedrine; Wikipedia: Pseudoephedrine
Psilocin
CA: CDSA Schedule III Section 11 Psilocin
UK: MDA Part I Class A Section 1(a) Psilocin
UN: Psychotropics Schedule I Psilocine (Psilotsin)
US: CSA Schedule I Section d Subsection 30 Psilocyn
Psilocine
CA: CDSA Schedule III Section 11 Psilocin
UK: MDA Part I Class A Section 1(a) Psilocin
UN: Psychotropics Schedule I Psilocine (Psilotsin)
US: CSA Schedule I Section d Subsection 30 Psilocyn
Psilocybin
CA: CDSA Schedule III Section 12 Psilocybin
UK: MDA Part I Class A Section 1(b) Psilocybin
UN: Psychotropics Schedule I Psilocybine
US: CSA Schedule I Section d Subsection 29 Psilocybin
⇒
PubChem: 10624; ChemSpider: 10178; Drugs Forum: 4-H2PO4-DMT; Erowid: Psilocybin & Psilocin; TiHKAL • info: 4-H2PO4-DMT; Wikipedia: Psilocybin
Psilocybine
CA: CDSA Schedule III Section 12 Psilocybin
UK: MDA Part I Class A Section 1(b) Psilocybin
UN: Psychotropics Schedule I Psilocybine
US: CSA Schedule I Section d Subsection 29 Psilocybin
⇒
PubChem: 10624; ChemSpider: 10178; Drugs Forum: 4-H2PO4-DMT; Erowid: Psilocybin & Psilocin; TiHKAL • info: 4-H2PO4-DMT; Wikipedia: Psilocybin
Psilocyn
CA: CDSA Schedule III Section 11 Psilocin
UK: MDA Part I Class A Section 1(a) Psilocin
UN: Psychotropics Schedule I Psilocine (Psilotsin)
US: CSA Schedule I Section d Subsection 30 Psilocyn
Psilotsin
CA: CDSA Schedule III Section 11 Psilocin
UK: MDA Part I Class A Section 1(a) Psilocin
UN: Psychotropics Schedule I Psilocine (Psilotsin)
US: CSA Schedule I Section d Subsection 30 Psilocyn
[3,2-c]Pyrazole-5α-androstan-17β-ol
UK: MDA Part III Class C Section 1(b) Prostanozol
US: CSA Schedule III Section f Subsection 1 Item 58 Prostanozol and Item 89 [3,2-c]Pyrazole-5α-androstan-17β-ol
![3D rendering of [3,2-c]Pyrazole-androst-4-en-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of [3,2-c]Pyrazole-androst-4-en-17β-ol")
[3,2-c]Pyrazole-androst-4-en-17β-ol
US: CSA Schedule III Section f Subsection 1 Item 88 [3,2-c]Pyrazole-androst-4-en-17β-ol
Pyrovalerone
CA: CDSA Schedule IV Section 26 Pyrovalerone
UK: MDA Part II Class B Section 1(aa) Pyrovalerone and Part III Class C Section 1(a) Pyrovalerone
UN: Psychotropics Schedule IV Pyrovalerone
US: CSA Schedule V Section d Subsection 1 Pyrovalerone
Pyrrolidine analog of Phencyclidine
CA: CDSA Schedule III Section 16 Rolicyclidine
UK: MDA Part I Class A Section 1(a) Rolicyclidine
UN: Psychotropics Schedule I Rolicyclidine (PHP) (PCPY)
US: CSA Schedule I Section d Subsection 33 Pyrrolidine analog of Phencyclidine
⇒
PubChem: 62436; ChemSpider: 56218; Bluelight: PCP analogs; Drugs Forum: PCP analogs; Erowid: Rolicyclidine synthesis; Wikipedia: Rolicyclidine
α-Pyrrolidinopentiophenone
US: CSA Schedule I Section h Subsection 13 alpha-Pyrrolidinopentiophenone
⇒
PubChem: 11148955; ChemSpider: 9324063; Drugs Forum: ?-PVP; Wikipedia: alpha-Pyrrolidinopentiophenone11 March 2016 · 
· Isomer Design
· Isomer Design